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LocalDeliveryof Heparinat CoronaryAngioplasty
Siteawiththe InfiltratorCatheter:Enhanced
IntramuralDrugDeposition
J.F. Mitchel, C.A. Pedereen, D.B. Fram, M.A. Azrin, F.J.Kieman,
R.G. McKay. Hariforrf Hospital, University of Connecticut, Hartford, CT USA
The Infiltrator is a new local d“mg delivery device that employs extruding
“nipples” on the catheter surface for direct intramural administration of ther-
apeutic agents. Tocompare the efficiency of drug deposition of this catheter
with other delivety techniques, 3H-heparin was administered following coro-
naiy angioplasfy in 29 porcine arteries either by the Infiltrator Catheter (2,500
unit.sh = 5), systemic heparin administration (22,500 unitah = 6), the lon-
tophoresis Catheter (20,000 unitaln = 6), the Dispatch Catheter (22,500
unitsln = 6), and the Hydrogel-Coated Balloon (3000 unitah = 6). Local
delivery of fluoresceinated-heparin was also performed in an additional 16
vessels to compare patterns of intramural drug deposition.
Results: Histologic analysis demonstrated fluorescent staining of thearte-
rial media and noevidence of vessel dissection in Infiltrator-treated vessels.
For all other devices, fluorescent medial staining was seen only along dis-
section planes at sitbs of vessel disruption.
Technique Units Deposited % IntramuralDeposition
Syetemic Infusion 0.01S units 0.00007%
Iontophoresis 3,4 units 0.017”/0
DiepatchCatheter 18.3 units 0.08%
HydrogelBalloon 3.0 unite 0,1%
InfiltratorCatheter 60.0 units 2.4%
Conclusions: The Infiltrator Catheter is more efficient than systemic ad-
ministration and other local delivety devices in the intramural deposition of
hepsrin at coronaw angioplasty sites. Madial deposition of drug is achieved
with the Infiltrator without significant disruption of vessel architecture.
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m7394 LocalIntramuralDeliveryof MK-0383,aPlateletGPllb/lllaReceptorBlocker,ReducesPlatelet
Depositionat the SiteofArterialInjury
N. Liu, D. H6bert, A.V. Kaplan, G. Grant, J.Y.T.Lam. Montreal Heart
Institute, Montreal, Quebec, Canada
Platelet thrombusformation atthesiteof arterial injury plays an important role
inthebiology of arterial injury. Local activation of platelets bythe injured arlery,
and cross-linking of glycoprotein GPllb/llla on activated platelets contributes
to platelet accretion on the injured arterial surface. Whether local delivery of
MK-03S3,a non-peptide inhibitor of platelet GPllb/llla receptorcsn decrease
acute platelet deposition on the injured artery was atudiad in normal Yorkshire
pigs (n = 6) undergoing carotid arterial injuiy by balloon angioplasty (5
inflations of 30 sac at 6 atm, with 1 min interval), followed by local intramural
delivery of 10 mg of MK-0383 in the right carotid, while the left carotid was
treated locally with saline control using a LocelMad infusion sleeve. PT and
PIT were not altered after local MK-0363 administration. Autologous CP1
Isballad platelet (PLT) deposition at the site of deep arterial injury, and the
degree of angiographic vasoconstriction at the aite of endothelial denudation
immediately distal, are shown below (mean + SEM);
Carotid PLT deposition Vaaoconstriction
(x 106/cm2) (% bsaeline)
Letf (control) 66.9 + 19.1 26.6 & 7.4
Right(MK-0383) 22.1 * 6,8” 11.4 + 4.8”
*p< 0.05 vs control
Thua, local intramural MK-03S3delivery reduces platalet deposition at the
site of deep arterial injury, as well as the platelet-dependent vasoconstrictive
reaponse following balloon angioplasfy, without altering systemic PT and
PTT.This may have clinical implication by Ibcally targeting effective platelet
inhibitor drug to the injury aite.
11:30
El7395 Reducingthe Riakof PercutaneousInterventionAfterCoronaryBypassSurgery:BeneficialEffects
of AbciximabTreatment
J.E. Tcheng, K. Anderaon, B.E. Tardiff, C.F. Cabot, A.M. Lincoff, R.M. Califf,
E.J. Topol. Duke University Medical CenteL Durham, NC, USA
Coronary intervention following bypass graft aurge~ (CABG) is associated
with high complication rates. In the EPIC and EPILOG trials, the platelet GP
llb/llla blocker abciximab (c7E3 Fab, ReoPro) was investigated in 4691 pts
of all risk strata undergoing corona~ intervention. Combining the 2 trials,
661 pts (13.5%) had undergone previoue CABG, with 223 randomized to
placebo, 95 to a single bolus of c7E3, and 343 to a bolus + 12 hr infueion
of c7E3. Meta-analysis revealed a 41.0% reduction in the composite 30 day
primary endpoint of death, myocardial infarction (Ml), and urgent intervention
with the bolus + infusion etrategy:
Death,MI,or Urgentinterventionto 30Days
m
1
— P=NS
15 13.9 I
p=.035
= ~ 11.8 I
“uiii-=
Cone/uaions:The risk of clinical complications in the post-CABG patient
treated with coronary intervention is increased; this risk cen,be reduced by
treatment with c7E3 Fab.
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1739-61Abciximab(c7E3~ab,Reopro)withReduced
HepsrinDosingDuringCoronaryIntervention:Final
Resultsof theEPILOGTrial
A.M. Lincoff, J.E. Tcheng, R.M. Califf, C.F. Cabot, D.P. Miller, J.E. Booth,
E.A. Montague, KM. Anderson, E.J, Topol. C/eve/and C/irric Foundation,
C/eve/and, Off, USA
To determine whether treatment with the platelet GP llb/llla receptor antag-
onist abciximab (Abcix) could reduce ischemic complications among all pts
undergoing coronary intervention, regardless of perceived ischemic risk, and
whether the incidence of bleeding with Abcix could be reduced by modifi-
cation of heparin dosing, 2792 pts were randomized in the EPILOG trial to:
placebo with “stendarddose” weight-adjusted heparin (Plac-Std; 100 U/kg
bolus, ACT >300 s), Abcix with “standard-dose” weight-adjusted heparin
(Abeix-Std), or Abcix with “low-dose” weight-adjusted heparin (Abcix-Low;
70 U/kg bolus, ACT z 200 s), The primary endpoint was the composite of
death, Ml (CK-MB > 3x or new Q-waves), or urgent repaat revascularization
by 30 d.
Event Rates Plac-Std* Abcix-Low* Abcix-Std P*
(%) n = 939 n = 935 n = 91S
Composite 11.7 5.2 5,4 <0,0001
Desth 0.6 0.3 0.4 NS
Ml 6.7 3.7 3.8 <O,wol
Death or Ml 9.1 3.8 4.2 <O,ooo1
Urgent Revaac 5.2 1.6 2.3 <0.001
Major Bleed 3.1 2.0 3.5 NS
Trsnsfuaion 3.9 2.4 3.8 NS
Abcix administered with reduced heparin dosing markedly reduces is-
chemic risk during coronary intervention without incremental major bleeding
risk. Complete 6-month follow-up data will also be presented.
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1740-1 I ClinicalConeeWen~aofMYocardialinfarction
FollowingBalloonAngioplaatyor Directional
CoronaryAtherectomy:AcuteandOneYearResufts
ofthe Balloonvs.OptimalAtherectomyTrial(BOAT)
D.E. Cutlip, D.S. Bairn, C. Senerchia, T. DeFeo-Fraulini, K.K.L. Ho,
M. Chauhan, N.-N. Chang, R.E. Kuntz. Beth /sree/ Hospita/, Boston, MA,
USA
Myocardial infarction (Ml) defined as elevation of creatine kinase MB isoen-
zyme (CK-MB) is a frequent occurrence following percutsneoue coronary in-
tewentiona. We examined whether post-procedural CK-MB elevations were
associated with adverse acute and one year clinical outcome, including mor-
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talify.The peak normalized CK-MB ratio (CKMBR) was determined and Ml
was classified as: Class 1, CKMBR >1 and <3 without EKG ST changes;
Clasa 2, CKMBR z 3 and s 8 or CKMBR >1 and <3 with EKG STchanges;
or Class 3, CKMBR >8 or Q wave ML Patients wera evaluated for 30 day
and one year mortality as well as a combined endpoint of death, follow-up
target vessel Ml or revascularization. One year follow-up is complete for 905
patients.
Ml Class PTCA DCA 30 day 30 day One year
[n =492] [n= 497] death endpoint death
n (%) n (%) n [“A] n [4A] n [ok]
1 37 (7.5) 80 (16,1) 1 10.q 4 [3.4 2 [1.q
2 23 (4.7) 61 (12.3) o 10.q 6 [7.1] o 10.q
3 11 (2.3) 31 (6.2) o 10.q 15 [35.71 o 10.q
Any Ml 71 (14.4) 172 (34.6) 1 [0.4 25 [10.4 2 IO,al
No Ml 404 (81.3) 310 (62.4) 1 [0.1] 5 [o.71 7 [l,q
Conclusions: 1) Ml occurred more frequently after DCAthan PTCA. 2) Ml
was associated with a higher incidence of the 30 day endpoint, due mainly to
abrupt closure, however,thera was no significantincreasein 30 day or one
year mortality.3) Data forthe combinedoneyear endpointwillbe presented.
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740-2 Coronary Intervention in the Diabetic Patient:
Improved Outcome Following Stent Implentetion
Veraue Balloon Angioplaaty
M.P, Savage, D.L. Fischman, P.Slota, R. Rake, M. Leon, R. Schatz,
J. Moses, 1.Penn, M. Nobuyoshi, R. Heuser, S. Goldberg. Jer7ersonMedical
Co//ege, Philadelphia, PA, USA
Recent studieshave demonstratedexcess morbidityand mortalityin dia-
beticpatientsundergoingcoronay angioplasty(PTCA) and haveauggested
superioroutcomeawithbypasasurgery.Sincathe roleof newtrarracatheter
interventionsinthispopulationisuncertain,we soughtto detenninawhether
stentplacementwas superiorto PTCA in diabeticswithcoronaryartetydis-
ease. Of 594 patientswith new lesionsof nativa coronatyarteries in the
randomized STRESS 1-IITrial, 92 (15.5%) were diabetic. Outcomes of the
47 disbeticsassigned to stent and the45 assigned to PTCAwere compard.
The two diabetic cohorts had similar baseline characteristics, veasel aize,
lesion length, and minimal lumen diameter (mId). Procedural angiographic
success waa superior in patienta aesigned to stenting (100% versus 82%, p
< 0.01). The diabeticgroupassignedto sterdshad greaterpost-procedural
mld (2.34 + 0.44 mm versus1.87 + 0.52 mm, p < 0.0001) and acutagain
(1.61 + 0.47 mmversus1.06+ 0.46 mm,p z O.OCO1).At6 months,mldwas
1.69 + 0.57 mm in the stentgroupand 1.38 + 0.60 mm in the PTCA group
(p= 0.03). Late IosaWasnotsignificantly different after stent or PTCA (0.71
k 0.53 mm veraus0.66 + 0.55 mm, p = ns), but net gainwas greaterwith
stenting(0.97 + 0.55 mm versus0.52 + 0.52 mm, p < 0.001). Restenosis
ratea were 60% in the PTCA group versus24% in the stent, group (p <
0.01). Thia was accompanied by a lower need for target lesion revascular-
ization after atanting (13% vereua 31%, p = 0.03). At one year, event-frea
euwival was 79% in the stent group and 84% in the PTCA group(p= 0.13).
Corrc/usiorrs.’Compared to balloon angioplasty, elective stent placement in
diabetic patients with coronary artety disease resutts in (i) superior procedu-
ral reaulte, (ii) lees restenoeia, and (iii) improved clinical outmme with fewer
repeat revascularization procedure.
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n7403 Stent Placement in Diabetic varaua Non-DiabeticPatients. Six-Month Angiographic Follow-Up
S. Elezi, H. Schuhlen, A. Wehinger, E. Zitzmann-Roth, H. Walter,
J. Haueleitar,J. Direchinger,A. Sch5mig. Deutsctresf-ferzzentnmrMikrchen,
Germarr~ 1.Medizinische Klinik, T~hnische Univereit#, Munich, Germany
Patients (pts) with diabetes (D) have a worse clinical outcome after PTCA in
comparison to non-diabetic patiente (ND). To etudy the angiogrephic follow-
UPof stented mronary lesions in pts with D, we comparad 190 D pts (248
lesions) versue 991 ND pts (1223 Ieaions) with successful atent placement.
Six-month angiographic follow-up waa performed in 134 D pts (70.5Yo)and
Diabetic Non-dhbetic p-valus
Acute gajn (mm) 2.18 + 0.62 2.23 & 0.65 ns
Elasticrecoil(mm) 0.30* 0.22 0.30 + 0.23 ns
Late 10ss(mm) 1,35 + 0.85 1.05 + 0.78 <0.0001
Loasjndex 0.5s* 0.34 0.50 & 0.42 0.003
% Diameterstenoala 47.1k 24.8 37,3& 23.3 <0.0001
Reocclusionrate 4.1% 2.6% na
Restenoajar te 39.6”A 23.6% <0.0001
in 716 ND pts (72.3%, p = 0.63), Quantitative angiographic analysis was
performed on per-lesion basic by edge detaction algorithm. Reatenosia waa
defined by a%diameter stenoais >50%. D pts did not differ from ND pte with
respect to veseel distribution, balloon size, balloon preeeure and reference
diameter before and after intervention,
Conclusions: Stent placement in diabetic patients can be achieved with
good acute angiographic results. Long-term angiographic outcome however,
is impaired by a significantly higher late loss and restenosis rata.
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1740-41 Does Diabetealnfluence Clinical RecurrenceAfier
Coronary Stent Implantation?
A. Abizaid, R. Mehran, T.A. Bucher, A. Greenberg, J.J. Popma, G.S. Minfz,
M.K. Hong, A.D. Pichard, K.M. Kent, L.F. Satler, M.B. Leon. Waahirrgton
Hospital CenteL Washington, DC, USA
Diabetes mellitus(DM) has consistentlybeen shown to strongly influance
the angiographic Ioes index and binary rastenoeis ratea after balloon PTCA
procedures. To determine if DM has eimilar effects on c/inica/ outcomes
in patients after native vessel corona~ stenting, we evaluated the acute
quantitative angiographic (QCA) rasults, major in-hospital complication (MC
=death, Q-wave Ml, or CABG), and late (>6 months) clinical outcome {target
lesion revascularization (TLR)) of 208 patiente with DM (96 pts requiring
insulin and 112 pts treated with oral therapy) compared to 662 non-diabetic
pts.
Non-DM Oral Insulin
In-hospitalMC (%) 1.2 2.6 2.9
OCA
Reference (mm) 3.00l 0.5 2.89iO.6* 2.67iO.6*
FinelMLD (mm) 2.73 k 0.5 2.52 +0.6”” 2.75 & 0,7
Final‘ADS 12.8* 14 16.9 + 15* 10.2 *15
TLR i%) 15,4 19.5 24.6**
*p < O.LZ;** p <0.01 comparedwithnon-diabaticpts
We conclude: (1)Major in-hospital complications are not significantly
different among DM pts (ineulin dependent ve non-insulin dependent). (2)
Reference veseej size is smaller in DM pts. (3) However, deapite similar
angiographic results, late outcomes ara clearfy worse in DM pta (asp. those
requiring insulin). Thus, although absolute TLR rates may be lower after
coronary stant therapy, insulin-requiring DM, in particular, still remaina an
important predictor of late clinical outcomes.
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174)-51 The’’FullMetalJacket’’: Procedural Fteauft6and
Late Clinical Outcomes after Placement of Three or
More Coronary Stents
R. Komowski, G.S. Mintz, R. Mehran, A.D. Pichard, K.M. Kent, L.F. Satler,
J.J. Popma, M.K. Hong, J.R. Laird, T.A. Bucher, D. Purkayaatha, M.B. Leon.
Washington Hospital Center, Washington, DC, USA
Previous studies have suggested higher reatenosia ratea in patients treated
with multiple etents. To determine the clinical outcomes in patients treated
with multiple (23) stents, we evaluated procedural success, major in-hospital
complication (Q wave Ml, CABG and death), subacute atent thromboaia,
and target lesion revascularization (TLR) at follow-up (>6 months) in 2,352
consecutive patients (3,310 lesions) treatad by one, two, or ?three etenta.
Multiple stents were implanted either for diffuae disease orexteneive dieeec-
tion in the setting of abruptlthreataned closure.
# Stents (# pta)
SVG/RCA (%)
Lesionlength(mm)
Prceedurasuccess
Maior complications
CKMB >5x nml
Subacutecloaure
TLR at follow-uD
Ona (1774)
32126
8.4 & 5.3
97.3%
2.1%
12.70/n
1.2”/0
11,2%
Two (499)
31/34
14.4 + 9.4
96.2%
3,0%
17.6%
0.6”/0
18,0Y0
?Three (79)
45/39
21.0 * 11,7
97.5%
2.5%
29.5%
2.5”/e
16.4%
Pvalue
0.043/0.005
<0.0001
0.57
0.37
<0.0001
0.26
<0.0001
We conclude.’ patients treated with 23 stenta (1) have aimilar in-hospital
procedural success and major complications, deapite significantly higher
CKMB elevation, and (2) manifest higher TLR than one-etent patients, (but
similar TLR vs. two-stent patiants). Thua, “full metal jacket” stent procedures
may be a viable therapeutic alternative in appropriate patients.
